deltatrials
Completed PHASE1 NCT01362374

Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors

A Phase Ib, Open-label, Dose-escalation Study of the Safety and Pharmacology of Ipatasertib (GDC-0068) in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors

Sponsor: Genentech, Inc.

Conditions Neoplasms
Interventions 5-FU Docetaxel Enzalutamide Ipatasertib Leucovorin Oxaliplatin Paclitaxel
Updated 17 times since 2017 Last updated: Jan 6, 2022 Started: Jul 11, 2011 Primary completion: Oct 16, 2020 Completion: Oct 16, 2020

Listed as NCT01362374, this PHASE1 trial focuses on Neoplasms and remains completed. Sponsored by Genentech, Inc., it has been updated 17 times since 2011, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Jun 2018 · 14 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Oct 2018 · 2 months · monthly snapshot~Oct 2018 – ~Jan 2019 · 3 months · monthly snapshot~Jan 2019 – ~Apr 2019 · 3 months · monthly snapshot~Apr 2019 – ~Aug 2019 · 4 months · monthly snapshot~Aug 2019 – ~Nov 2019 · 3 months · monthly snapshot~Nov 2019 – ~Jan 2020 · 2 months · monthly snapshot~Jan 2020 – ~Jul 2020 · 6 months · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Feb 2022 · 13 months · monthly snapshot~Feb 2022 – ~Jul 2024 · 29 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 19 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Feb 2022 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jan 2021 — Feb 2022 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  5. Aug 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

▶ Show 12 earlier versions

  1. Jul 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE1

  2. Jan 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE1

  3. Nov 2019 — Jan 2020 [monthly]

    Active Not Recruiting PHASE1

  4. Aug 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE1

  5. Apr 2019 — Aug 2019 [monthly]

    Active Not Recruiting PHASE1

  6. Jan 2019 — Apr 2019 [monthly]

    Active Not Recruiting PHASE1

  7. Oct 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE1

  8. Aug 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE1

  9. Jun 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE1

  10. Apr 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

  11. Feb 2017 — Apr 2017 [monthly]

    Active Not Recruiting PHASE1

  12. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1

    First recorded

Jul 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Genentech, Inc.
Data source: Genentech, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Barcelona, Spain , Boston, United States , Las Vegas, United States , Nashville, United States , Norfolk, United States , San Francisco, United States , Sarasota, United States , Sutton, United Kingdom , Valencia, Spain and 1 more location